Article: Breast cancer polygenic risk scores derived in White European populations are not calibrated for women of Ashkenazi Jewish descent
Name:
37061873.pdf
Size:
1.156Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Roberts, E.van Veen, E. M.
Byers, H.
Barnett-Griness, O.
Gronich, N.
Lejbkowicz, F.
Pinchev, M.
Smith, M. J.
Howell, Anthony
Newman, W. G.
Woodward, E. R.
Harkness, E. F.
Brentnall, A. R.
Cuzick, J.
Rennert, G.
Howell, Sacha J
Evans, D Gareth R
Affiliation
Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UKIssue Date
2023
Metadata
Show full item recordAbstract
Purpose: Polygenic risk scores (PRS) are a major component of accurate breast cancer (BC) risk prediction but require ethnicity-specific calibration. Ashkenazi-Jews-(AJ) are assumed to be of White-European-(WE) origin in some commercially-available PRS despite differing effect-allele-frequencies-(EAFs). We conducted a case-control study of WE and AJ women from the PROCAS-(Predicting-Risk-of-Cancer-at-Screening) study. The BCINIS-(Breast-Cancer-in-Northern-Israel-study) provided a separate AJ population-based case-control validation series. Methods: All women underwent Illumina Oncoarray SNP-analysis. Two PRS were assessed, SNP142&SNP78. 221/2243 WE (Discovery:cases=111;controls=110;Validation:cases=651;controls=1772) and 221 AJ (cases=121;controls=110) women were included from the UK study; the Israeli series consisted of 2045 AJ women (cases=1331;controls=714). EAFs were obtained from gnomAD. Results: In the UK study the mean SNP142PRS demonstrated good calibration and discrimination in WEs: mean PRS in cases=1.33-(95%CI=1.18-1.48) and controls=1.01-(95%CI=0.89-1.13). In AJs from Manchester, the mean PRS in cases=1.54-(1.38-1.70) and controls=1.20-(1.08-1.32) demonstrated good discrimination but overestimation of BC relative-risk. After adjusting for AJ EAFs, mean risk was corrected (mean SNP142-PRS cases=1.30-(95%CI=1.16-1.44) and controls=1.02-(95%CI=0.92-1.12)). This was recapitulated in the larger Israeli dataset with good discrimination (AUC=0.632-(95%CI=0.607-0.657) for SNP142). Conclusion: AJ women should not be given BC relative-risk predictions based on PRS calibrated to EAFs from WEs. PRS need to be recalibrated using AJ-derived-EAFs. A simple recalibration using the mean PRS adjustment ratio likely performs well.Citation
Roberts E, van Veen EM, Byers H, Barnett-Griness O, Gronich N, Lejbkowicz F, et al. Article: Breast cancer polygenic risk scores derived in White European populations are not calibrated for women of Ashkenazi Jewish descent. Genetics in medicine : official journal of the American College of Medical Genetics. 2023 Apr 12:100846. PubMed PMID: 37061873. Epub 2023/04/17. eng.Journal
Genetics in MedicineDOI
10.1016/j.gim.2023.100846PubMed ID
37061873Additional Links
https://dx.doi.org/10.1016/j.gim.2023.100846Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.gim.2023.100846
Scopus Count
Collections
Related articles
- Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel.
- Authors: Levi H, Carmi S, Rosset S, Yerushalmi R, Zick A, Yablonski-Peretz T, BCAC Consortium, Wang Q, Bolla MK, Dennis J, Michailidou K, Lush M, Ahearn T, Andrulis IL, Anton-Culver H, Antoniou AC, Arndt V, Augustinsson A, Auvinen P, Beane Freeman L, Beckmann M, Behrens S, Bermisheva M, Bodelon C, Bogdanova NV, Bojesen SE, Brenner H, Byers H, Camp N, Castelao J, Chang-Claude J, Chirlaque MD, Chung W, Clarke C, NBCS Collaborators, Collee MJ, Colonna S, CTS Consortium, Couch F, Cox A, Cross SS, Czene K, Daly M, Devilee P, Dork T, Dossus L, Eccles DM, Eliassen AH, Eriksson M, Evans G, Fasching P, Fletcher O, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, García-Closas M, Garcia-Saenz JA, Genkinger J, Giles GG, Goldberg M, Guénel P, Hall P, Hamann U, He W, Hillemanns P, Hollestelle A, Hoppe R, Hopper J, ABCTB Investigators, Jakovchevska S, Jakubowska A, Jernström H, John E, Johnson N, Jones M, Vijai J, Kaaks R, Khusnutdinova E, Kitahara C, Koutros S, Kristensen V, Kurian AW, Lacey J, Lambrechts D, Le Marchand L, Lejbkowicz F, Lindblom A, Loibl S, Lori A, Lubinski J, Mannermaa A, Manoochehri M, Mavroudis D, Menon U, Mulligan A, Murphy R, Nevelsteen I, Newman WG, Obi N, O'Brien K, Offit K, Olshan A, Plaseska-Karanfilska D, Olson J, Panico S, Park-Simon TW, Patel A, Peterlongo P, Rack B, Radice P, Rennert G, Rhenius V, Romero A, Saloustros E, Sandler D, Schmidt MK, Schwentner L, Shah M, Sharma P, Simard J, Southey M, Stone J, Tapper WJ, Taylor J, Teras L, Toland AE, Troester M, Truong T, van der Kolk LE, Weinberg C, Wendt C, Yang XR, Zheng W, Ziogas A, Dunning AM, Pharoah P, Easton DF, Ben-Sachar S, Elefant N, Shamir R, Elkon R
- Issue date: 2023 Nov 27
- Genome wide association study and genomic risk prediction of age related macular degeneration in Israel.
- Authors: Grunin M, Triffon D, Beykin G, Rahmani E, Schweiger R, Tiosano L, Khateb S, Hagbi-Levi S, Rinsky B, Munitz R, Winkler TW, Heid IM, Halperin E, Carmi S, Chowers I
- Issue date: 2024 Jun 6
- The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin?
- Authors: Evans DG, van Veen EM, Byers H, Roberts E, Howell A, Howell SJ, Harkness EF, Brentnall A, Cuzick J, Newman WG
- Issue date: 2022 Jan 1
- Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation.
- Authors: Rinella ES, Shao Y, Yackowski L, Pramanik S, Oratz R, Schnabel F, Guha S, LeDuc C, Campbell CL, Klugman SD, Terry MB, Senie RT, Andrulis IL, Daly M, John EM, Roses D, Chung WK, Ostrer H
- Issue date: 2013 May
- Polygenic risk scores for the prediction of common cancers in East Asians: A population-based prospective cohort study.
- Authors: Ho PJ, Tan IB, Chong DQ, Khor CC, Yuan JM, Koh WP, Dorajoo R, Li J
- Issue date: 2023 Mar 27